Quarterly ResultApr 29, 2026, 07:56 AM
ABBV Q1 Revenue $15.002B, +12.4%; Adj. EPS $2.65, +7.7%; Raises 2026 EPS Guidance
AI Summary
AbbVie Inc. reported strong first-quarter 2026 financial results, with net revenues reaching $15.002 billion, a 12.4% increase, and adjusted diluted EPS growing 7.7% to $2.65. The company exceeded expectations and raised its full-year 2026 adjusted diluted EPS guidance to $14.08 - $14.28. Key growth drivers like Skyrizi, Rinvoq, and the Neuroscience portfolio delivered robust performance, while the company also announced a new FDA approval for Venclexta and submitted applications for Skyrizi and Rinvoq for new indications, though it received a CRL for trenibotulinumtoxinE due to manufacturing process inquiries.
Key Highlights
- Q1 Net Revenues were $15.002 billion, an increase of 12.4% on a reported basis.
- Q1 Adjusted Diluted EPS was $2.65, an increase of 7.7%; GAAP Diluted EPS was $0.39, a decrease of 45.8%.
- Raises 2026 Adjusted Diluted EPS guidance range to $14.08 - $14.28.
- Immunology portfolio net revenues were $7.290 billion, up 16.4% reported, driven by Skyrizi ($4.483B) and Rinvoq ($2.119B).
- Neuroscience portfolio net revenues were $2.875 billion, up 26.0% reported, with Botox Therapeutic ($1.009B) and Vraylar ($905M).
- FDA approved Venclexta and acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL).
- FDA issued a Complete Response Letter (CRL) for trenibotulinumtoxinE BLA, requesting additional manufacturing information.